Monday, August 25, 2014
9 a.m. – 5 p.m.
Sumner M. Redstone Building, Room 101
Recently, the US Supreme Court ruled in Association for Molecular Pathology v. Myriad Genetics that a human gene implicated in breast and ovarian cancer was not patentable subject matter. In Mayo v. Prometheus, the Court also recently ruled that a method for optimizing certain drug therapies was not patentable subject matter.

BU Law will host a conference to examine the potential impact of these rulings on medical research. The Kauffman Foundation will fund the conference, which will bring together legal, business, medical, and economic experts to discuss the impact of these cases, and generally the impact of patent and trade secret law on the incentives for innovation in the field of personalized medicine.

This event is free and open to the public. To register, email lawevent@bu.edu.